14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
IBRX vs MRNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over ImmunityBio, Inc. (IBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). IBRX carries a Unified Composite Score of 61.4/100 (BUY) at $6.02 (60.2x Forward P/E, -150.2% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).
Composite vs. Pillar Nuance: While IBRX currently prints a higher short-term Unified Composite Score (61.4/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -150.2% operating margin) and revenue trajectory (+29.2% vs. +52.3% YoY).
Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.8); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
Investor FAQ IBRX vs MRNA Key Questions & Quantitative Answers
As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over ImmunityBio, Inc. (IBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). IBRX carries a Unified Composite Score of 61.4/100 (BUY) at $6.02 (60.2x Forward P/E, -150.2% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Composite vs. Pillar Nuance: While IBRX currently prints a higher short-term Unified Composite Score (61.4/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -150.2% operating margin) and revenue trajectory (+29.2% vs. +52.3% YoY). Technical & Structure Timing Caution: IBRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.8); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBRX leads the Growth & Scale pillar: IBRX posts +52.3% YoY revenue growth and +0.0% YoY earnings growth on $183M TTM revenue (98.8% gross margin, -150.2% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IBRX cumulative revenue shifted +1000.0% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, IBRX deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.
MRNA screens cheaper on headline valuation multiples. IBRX trades at 60.2x Forward P/E, 60.2x Trailing P/E, N/M PEG, and 42.8x EV/Revenue (unreported FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBRX (0.0% ROE) versus MRNA (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, IBRX carries 86.8% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.68x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 107% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.